William Burke - 05 Nov 2025 Form 4 Insider Report for Axogen, Inc. (AXGN)

Role
Director
Signature
/s/ Marc Began, as attorney-in-fact for William Burke
Issuer symbol
AXGN
Transactions as of
05 Nov 2025
Transactions value $
-$266,691
Form type
4
Filing time
07 Nov 2025, 16:52:34 UTC
Previous filing
31 Oct 2025
Next filing
13 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Burke William P. Mr. Director C/O AXOGEN, INC. 13631 PROGRESS BLVD., SUITE 400, ALACHUA /s/ Marc Began, as attorney-in-fact for William Burke 07 Nov 2025 0001682069

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXGN Common Stock Options Exercise $93K +11.4K +11431% $8.14 11.5K 05 Nov 2025 Direct
transaction AXGN Common Stock Sale -$275K -11.4K -99.13% $24.05 100 05 Nov 2025 Direct F1
transaction AXGN Common Stock Options Exercise $43.5K +5.35K +5347% $8.14 5.45K 06 Nov 2025 Direct
transaction AXGN Common Stock Sale -$128K -5.35K -98.16% $24.01 100 06 Nov 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXGN Stock Option (right to purchase) Options Exercise $0 -11.4K -28.87% $0.00 28.2K 05 Nov 2025 Common Stock 11.4K $8.14 Direct F3
transaction AXGN Stock Option (right to purchase) Options Exercise $0 -5.35K -18.98% $0.00 22.8K 06 Nov 2025 Common Stock 5.35K $8.14 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.25 per share. The Reporting Person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F2 The sale reported on this Form 4 was made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.06 per share. The Reporting Person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 This grant vested in three equal annual installments on the annual anniversary of the grant date, July 11, 2022.